Edwards Lifesciences Corporation Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Edwards Lifesciences Corporation (EW) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $241.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-04
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $241.40M, a 27.18% decline year-over-year.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $380.70M, a 6.82% increase year-over-year.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $91.20M, a 76.27% decline year-over-year.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $290.30M, a 90.54% decline year-over-year.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $1.07B, a 74.35% decline from fiscal 2024.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $4.17B, a 197.96% increase from fiscal 2023.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $1.40B, a 8.05% decline from fiscal 2022.
- Edwards Lifesciences Corporation net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $1.52B, a 1.25% increase from fiscal 2021.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $241.40M 10-Q · filed 2026-08-04 | $622.10M 10-Q · filed 2026-08-04 | $713.30M derived: sum of 3 quarters · filed 2026-08-04 | $1.00B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $380.70M 10-Q · filed 2026-08-04 | $471.90M derived: sum of 2 quarters · filed 2026-08-04 | $762.20M derived: sum of 3 quarters · filed 2026-08-04 | $1.09B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $91.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $381.50M derived: sum of 2 quarters · filed 2026-02-25 | $713.00M derived: sum of 3 quarters · filed 2026-08-04 | $1.07B 10-K · filed 2026-02-25 |
| 2025-09-30 | $290.30M 10-Q · filed 2025-11-05 | $621.80M derived: sum of 2 quarters · filed 2026-08-04 | $978.20M 10-Q · filed 2025-11-05 | $1.36B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $331.50M 10-Q · filed 2026-08-04 | $687.90M 10-Q · filed 2026-08-04 | $1.07B derived: sum of 3 quarters · filed 2026-08-04 | $4.14B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $356.40M 10-Q · filed 2026-08-04 | $740.70M derived: sum of 2 quarters · filed 2026-08-04 | $3.81B derived: sum of 3 quarters · filed 2026-08-04 | $4.18B derived: sum of 4 quarters · filed 2026-08-04 |
| 2024-12-31 | $384.30M 10-K · filed 2025-02-28 | $3.45B derived: sum of 2 quarters · filed 2025-11-05 | $3.82B derived: sum of 3 quarters · filed 2025-11-05 | $4.17B 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.07B 10-Q · filed 2025-11-05 | $3.43B derived: sum of 2 quarters · filed 2025-11-05 | $3.79B 10-Q · filed 2025-11-05 | $4.16B derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $365.00M 10-Q · filed 2025-11-05 | $716.00M 10-Q · filed 2025-08-06 | $1.09B derived: sum of 3 quarters · filed 2025-11-05 | $1.47B derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-03-31 | $351.00M 10-Q · filed 2025-11-05 | $720.70M derived: sum of 2 quarters · filed 2025-11-05 | $1.10B derived: sum of 3 quarters · filed 2025-11-05 | $1.41B derived: sum of 4 quarters · filed 2025-11-05 |
| 2023-12-31 | $369.70M 10-K · filed 2025-02-28 | $753.40M derived: sum of 2 quarters · filed 2025-02-28 | $1.06B derived: sum of 3 quarters · filed 2025-02-28 | $1.40B 10-K · filed 2026-02-25 |
| 2023-09-30 | $383.70M 10-K · filed 2025-02-28 | $689.20M derived: sum of 2 quarters · filed 2025-02-28 | $1.03B 10-Q · filed 2024-11-06 | $1.43B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $305.50M 10-K · filed 2025-02-28 | $646.00M 10-Q · filed 2024-07-31 | $1.04B derived: sum of 3 quarters · filed 2025-02-28 | $1.39B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $340.50M 10-K · filed 2025-02-28 | $738.90M derived: sum of 2 quarters · filed 2025-02-28 | $1.08B derived: sum of 3 quarters · filed 2025-02-28 | $1.49B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $398.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $741.90M derived: sum of 2 quarters · filed 2025-02-28 | $1.15B derived: sum of 3 quarters · filed 2025-02-28 | $1.52B 10-K · filed 2025-02-28 |
| 2022-09-30 | $343.50M 10-Q · filed 2023-10-27 | $749.90M derived: sum of 2 quarters · filed 2023-10-27 | $1.12B 10-Q · filed 2023-10-27 | |
| 2022-06-30 | $406.40M 10-Q · filed 2023-10-27 | $780.00M 10-Q · filed 2023-07-28 | ||
| 2022-03-31 | $373.60M 10-Q · filed 2023-10-27 | |||
| 2021-12-31 | $1.50B 10-K · filed 2024-02-12 | |||
| 2011-06-30 | $58.10M 10-Q · filed 2011-08-08 | $122.00M 10-Q · filed 2011-08-08 | $186.80M derived: sum of 3 quarters · filed 2011-08-08 | $234.80M derived: sum of 4 quarters · filed 2011-08-08 |
| 2011-03-31 | $63.90M 10-Q · filed 2011-05-09 | $128.70M derived: sum of 2 quarters · filed 2011-05-09 | $176.70M derived: sum of 3 quarters · filed 2011-05-09 | $234.20M derived: sum of 4 quarters · filed 2011-08-08 |
| 2010-12-31 | $64.80M 10-K · filed 2011-02-28 | $112.80M derived: sum of 2 quarters · filed 2011-02-28 | $170.30M derived: sum of 3 quarters · filed 2011-08-08 | $218.00M 10-K · filed 2011-02-28 |
| 2010-09-30 | $48.00M 10-K · filed 2011-02-28 | $105.50M derived: sum of 2 quarters · filed 2011-08-08 | $153.20M 10-Q · filed 2010-11-08 | $200.80M derived: sum of 4 quarters · filed 2011-08-08 |
| 2010-06-30 | $57.50M 10-Q · filed 2011-08-08 | $105.20M 10-Q · filed 2011-08-08 | $152.80M derived: sum of 3 quarters · filed 2011-08-08 | $226.30M derived: sum of 4 quarters · filed 2011-08-08 |
| 2010-03-31 | $47.70M 10-Q · filed 2011-05-09 | $95.30M derived: sum of 2 quarters · filed 2011-05-09 | $168.80M derived: sum of 3 quarters · filed 2011-05-09 | $216.30M derived: sum of 4 quarters · filed 2011-05-09 |
| 2009-12-31 | $47.60M 10-K · filed 2011-02-28 | $121.10M derived: sum of 2 quarters · filed 2011-02-28 | $168.60M derived: sum of 3 quarters · filed 2011-02-28 | $229.10M 10-K · filed 2011-02-28 |
| 2009-09-30 | $73.50M 10-K · filed 2011-02-28 | $121.00M derived: sum of 2 quarters · filed 2011-02-28 | $181.50M 10-Q · filed 2010-11-08 | |
| 2009-06-30 | $47.50M 10-K · filed 2011-02-28 | $108.00M 10-Q · filed 2010-08-06 | ||
| 2009-03-31 | $60.50M 10-K · filed 2011-02-28 | |||
| 2008-12-31 | $128.90M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |